ATE364625T1 - Proteine aus yaba monkey tumor virus mit modulatorischer aktivität - Google Patents

Proteine aus yaba monkey tumor virus mit modulatorischer aktivität

Info

Publication number
ATE364625T1
ATE364625T1 AT01999573T AT01999573T ATE364625T1 AT E364625 T1 ATE364625 T1 AT E364625T1 AT 01999573 T AT01999573 T AT 01999573T AT 01999573 T AT01999573 T AT 01999573T AT E364625 T1 ATE364625 T1 AT E364625T1
Authority
AT
Austria
Prior art keywords
proteins
tumor virus
yaba monkey
monkey tumor
modulatory activity
Prior art date
Application number
AT01999573T
Other languages
English (en)
Inventor
Grant Mcfadden
Alexandra Lucas
Xing Li
Original Assignee
Viron Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viron Therapeutics Inc filed Critical Viron Therapeutics Inc
Application granted granted Critical
Publication of ATE364625T1 publication Critical patent/ATE364625T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
AT01999573T 2000-12-04 2001-12-04 Proteine aus yaba monkey tumor virus mit modulatorischer aktivität ATE364625T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25114700P 2000-12-04 2000-12-04

Publications (1)

Publication Number Publication Date
ATE364625T1 true ATE364625T1 (de) 2007-07-15

Family

ID=22950675

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01999573T ATE364625T1 (de) 2000-12-04 2001-12-04 Proteine aus yaba monkey tumor virus mit modulatorischer aktivität

Country Status (11)

Country Link
US (1) US7101559B2 (de)
EP (1) EP1339737B1 (de)
JP (3) JP4472252B2 (de)
AT (1) ATE364625T1 (de)
AU (2) AU1572702A (de)
CA (1) CA2428097A1 (de)
DE (1) DE60128950T2 (de)
DK (1) DK1339737T3 (de)
ES (1) ES2287192T3 (de)
PT (1) PT1339737E (de)
WO (1) WO2002046214A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002211744B8 (en) 2000-10-11 2008-03-20 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
EP1339737B1 (de) 2000-12-04 2007-06-13 Viron Therapeutics, Inc. Proteine aus yaba monkey tumor virus mit modulatorischer aktivität
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
US8251876B2 (en) 2008-04-22 2012-08-28 Hill-Rom Services, Inc. Breathing exercise apparatus
US9180271B2 (en) 2012-03-05 2015-11-10 Hill-Rom Services Pte. Ltd. Respiratory therapy device having standard and oscillatory PEP with nebulizer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US38203A (en) * 1863-04-14 Improved strike for door-locks
US5651972A (en) * 1989-04-21 1997-07-29 University Of Florida Research Foundation, Inc. Use of recombinant swine poxvirus as a live vaccine vector
AU646695B2 (en) 1990-04-09 1994-03-03 Immunex Corporation Isolated viral protein cytokine antagonists
DE69104356T2 (de) 1990-04-24 1995-03-02 Schering Corp Lösliche verkürzte interferon-gamma rezeptoren.
DK0754054T3 (da) * 1994-04-08 2002-10-14 Viron Therapeutics Inc Antirestenosis-protein
US5656465A (en) * 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US5939525A (en) * 1995-03-27 1999-08-17 Viron Therapeutics, Inc. Methods of treating inflammation and compositions therefor
US6495515B1 (en) * 1995-04-19 2002-12-17 Viron Therapeutics, Inc. Chemokine binding protein and methods of use therefor
PT840615E (pt) * 1995-04-19 2003-10-31 Robarts John P Res Inst Proteina de ligacao da quemoquina e metodos para a sua utilizacao
JPH11514861A (ja) 1995-09-29 1999-12-21 イミュネックス・コーポレーション ケモカインインヒビター
EP1034789A1 (de) * 1996-05-22 2000-09-13 University Of Alberta Typ-2 Chemokine-Bindende Proteine und Verfahren zu deren Verwendung
PL330149A1 (en) 1996-05-22 1999-04-26 Univ Alberta Bonding chemokins of type ii proteins and method of applying them
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
US6589933B1 (en) * 1999-04-02 2003-07-08 Viron Therapeutics, Inc. Myxoma chemokine binding protein
AU2001240109A1 (en) * 2000-03-07 2001-09-17 U.S. Army Medical Research Institute Of Infectious Diseases Dna vaccines against poxviruses
AU2002211744B8 (en) * 2000-10-11 2008-03-20 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
EP1339737B1 (de) 2000-12-04 2007-06-13 Viron Therapeutics, Inc. Proteine aus yaba monkey tumor virus mit modulatorischer aktivität

Also Published As

Publication number Publication date
DE60128950D1 (de) 2007-07-26
WO2002046214A2 (en) 2002-06-13
JP2004522427A (ja) 2004-07-29
US7101559B2 (en) 2006-09-05
EP1339737B1 (de) 2007-06-13
JP2010077136A (ja) 2010-04-08
WO2002046214A3 (en) 2002-09-26
CA2428097A1 (en) 2002-06-13
DK1339737T3 (da) 2007-10-15
ES2287192T3 (es) 2007-12-16
AU1572702A (en) 2002-06-18
DE60128950T2 (de) 2008-02-28
EP1339737A2 (de) 2003-09-03
PT1339737E (pt) 2007-09-03
JP2009227686A (ja) 2009-10-08
AU2002215727B8 (en) 2008-02-21
US20040038203A1 (en) 2004-02-26
JP4472252B2 (ja) 2010-06-02
AU2002215727B9 (en) 2008-02-21
AU2002215727B2 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
ATE360808T1 (de) Unabhängiges gerät zur extraktion, amplifikation und nachweis von nukleinsäuren
EP1436429A4 (de) Zielnukleinsäurekonstrukte und damit verbundene verwendungen
WO2003016499A3 (en) Combinatorial methods for inducing cancer cell death
DE69819124D1 (de) Lyophilisation von kultivierten, menschlichen zellen zur konservierung der rna und dna
NO20055838L (no) Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav
WO2000053776A3 (en) Human kallikrein-like genes
DE60139544D1 (de) Veränderte, fluoreszierende proteine
EP1536006A4 (de) Krebsantigene und deren nutzung
WO2005000335A3 (en) Use of genes differentially expressed during aging of liver for treatment and diagnosis
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
DE69833876D1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
DE60128950D1 (de) Proteine aus yaba monkey tumor virus mit modulatorischer aktivität
WO2001040313A3 (en) Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
WO2005042719A3 (en) Methods for treating and preventing ischemia-reperfusion injury using rna interfering agents
WO2004070012A3 (en) Cell-killing molecules and methods of use thereof
DE60107888D1 (de) Beta-Interferon zur Behandlung von Immunerkrankungen
EP1409710A4 (de) Nukleinsäure und dieser entsprechendes, 161p5c5 genanntes, für die behandlung und den nachweis von krebs geeignetes protein
WO2004113386A3 (en) Modified hirudin proteins and t-cell epitopes in hirudin
AP2781A (en) Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereof
ATE255594T1 (de) Hepatitis b inhibitoren
NL1020885A1 (nl) Glutaminase, glutaminasegen, nieuw recombinant DNA en werkwijze voor de bereiding van glutaminase.
WO2000065063A3 (en) Nucleic acid vaccines against rickettsial diseases and methods of use
WO2002011549A3 (en) Treatment of mycobacterial infection

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1339737

Country of ref document: EP